Clinical Trial Update: Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on maintenance Erlotinib (Tarceva) after locally advanced head and neck cancer treatment; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Geisinger Clinic | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-02-05